GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Xencor Inc (NAS:XNCR) » Definitions » Cyclically Adjusted PB Ratio

Xencor (Xencor) Cyclically Adjusted PB Ratio : 2.42 (As of May. 31, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Xencor Cyclically Adjusted PB Ratio?

As of today (2024-05-31), Xencor's current share price is $23.89. Xencor's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $9.86. Xencor's Cyclically Adjusted PB Ratio for today is 2.42.

The historical rank and industry rank for Xencor's Cyclically Adjusted PB Ratio or its related term are showing as below:

XNCR' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 1.79   Med: 3.27   Max: 6.41
Current: 2.35

During the past years, Xencor's highest Cyclically Adjusted PB Ratio was 6.41. The lowest was 1.79. And the median was 3.27.

XNCR's Cyclically Adjusted PB Ratio is ranked worse than
59.24% of 655 companies
in the Biotechnology industry
Industry Median: 1.76 vs XNCR: 2.35

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Xencor's adjusted book value per share data for the three months ended in Mar. 2024 was $9.938. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $9.86 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Xencor Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Xencor's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xencor Cyclically Adjusted PB Ratio Chart

Xencor Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 6.41 3.16 2.23

Xencor Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.30 2.80 2.16 2.23 2.24

Competitive Comparison of Xencor's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Xencor's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xencor's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Xencor's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Xencor's Cyclically Adjusted PB Ratio falls into.



Xencor Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Xencor's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=23.89/9.86
=2.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xencor's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Xencor's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=9.938/131.7762*131.7762
=9.938

Current CPI (Mar. 2024) = 131.7762.

Xencor Quarterly Data

Book Value per Share CPI Adj_Book
201406 2.087 100.560 2.735
201409 1.902 100.428 2.496
201412 1.886 99.070 2.509
201503 4.195 99.621 5.549
201506 4.006 100.684 5.243
201509 3.788 100.392 4.972
201512 4.006 99.792 5.290
201603 3.898 100.470 5.113
201606 5.095 101.688 6.603
201609 4.920 101.861 6.365
201612 6.742 101.863 8.722
201703 6.506 102.862 8.335
201706 6.432 103.349 8.201
201709 6.188 104.136 7.830
201712 6.733 104.011 8.530
201803 9.667 105.290 12.099
201806 9.301 106.317 11.528
201809 9.469 106.507 11.716
201812 9.269 105.998 11.523
201903 10.818 107.251 13.292
201906 10.757 108.070 13.117
201909 10.760 108.329 13.089
201912 10.425 108.420 12.671
202003 10.403 108.902 12.588
202006 9.974 108.767 12.084
202009 9.908 109.815 11.889
202012 9.891 109.897 11.860
202103 10.024 111.754 11.820
202106 11.094 114.631 12.753
202109 10.587 115.734 12.054
202112 12.358 117.630 13.844
202203 12.818 121.301 13.925
202206 12.438 125.017 13.110
202209 12.091 125.227 12.723
202212 12.125 125.222 12.760
202303 11.321 127.348 11.715
202306 11.203 128.729 11.468
202309 11.028 129.860 11.191
202312 10.964 129.419 11.164
202403 9.938 131.776 9.938

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Xencor  (NAS:XNCR) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Xencor Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Xencor's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Xencor (Xencor) Business Description

Industry
Traded in Other Exchanges
Address
111 West Lemon Avenue, Monrovia, CA, USA, 91016
Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045 and XmAb13676. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.
Executives
Bassil I Dahiyat director, officer: PRESIDENT & CEO C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Barbara Klencke director C/O SIERRA ONCOLOGY, INC., 1820 GATEWAY DRIVE, SUITE 110, SAN MATEO CA 94404
Allen Yang officer: SR. VICE PRESIDENT & CMO C/O XENCOR INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Celia Eckert officer: VP, GENERAL COUNSEL C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
John R Desjarlais officer: SR. VICE PRESIDENT & CSO C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
John J Kuch officer: SR. VICE PRESIDENT & CFO C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Nancy Valente director C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Richard J Ranieri director 3005 FIRST AVE, SEATTLE WA 98121
Ellen Feigal director C/O XENCOR INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Yujiro S Hata director C/O XENCOR, INC., 111 WEST LEMON AVENUE, MONROVIA CA 91016
Dagmar Rosa-bjorkeson director C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015
Alan Bruce Montgomery director 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Kevin Charles Gorman director 12790 EL CAMINO REAL, SAN DIEGO CA 92130
Kurt A Gustafson director 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA 92121
Stafford John S Iii 10 percent owner 230 SOUTH LASALLE STREET 400, CHICAGO IL 60604